Digital technologies in prostate cancer prevention and early diagnosis

Cover Page


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Background. Prostate cancer is one of the most common malignant neoplasms in males. The Russian Federation observed the same patterns: the incidence of prostate cancer is steadily growing, without the tendency to decrease. Currently, no effective methods are available for prostate cancer early diagnosis and screening.

Aim. To improve the effectiveness of prostate cancer prevention and early diagnosis with new digital technologies for high-risk cancer group formation

Material and methods. Data from the Cancer Registry population in the “Altai regional cancer center,” Barnaul City was used. The Cancer Registry includes information about 253,000 patients with malignant neoplasms, including 14,482 males suffering from prostate cancer. Based on the targeted prevention method of A.F. Lazarev, “Method for determining the risk of prostate cancer” (Patent 2692987) and “Automated program for early diagnosis of prostate cancer” (certificate of state registration of the computer program No. 2019663514) was developed, which simplifies the stage of forming groups of precancerous high oncorisk and increases prostate cancer detection, as well as develops personalized targeted preventive measures for each patient.

Results. The study formed a group of 328 patients with precancerous high oncorisk for prostate cancer in the Cancer Registry, wherein an in-depth examination revealed 26 patients with prostate cancer, which was 7.9%. Stages I and II were established in 97.8%.

Conclusion. The web application “Automated program for early diagnosis of prostate cancer” allows the group formation of high-risk patients who are a targeted search for prostate cancer. The testing process allows a large number of patients to be examined in a short time. The “automated program for the early diagnosis of prostate cancer” allows a statistically significant increased prostate cancer detection, as well as personalized preventive measure suggestions for each patient.

Full Text

Restricted Access

About the authors

A. F. Lazarev

Altai State Medical University (ASMU)

Email: valent_04@mail.ru
ORCID iD: 0000-0003-1080-5294
Russian Federation, 40, Lenin Ave., Barnaul, 656038

Valentina D. Petrova

Altai State Medical University (ASMU)

Author for correspondence.
Email: valent_04@mail.ru
ORCID iD: 0000-0001-7169-9646

Ph.D.

Russian Federation, 40, Lenin Ave., Barnaul, 656038

V. P. Pokornyak

OOO “Scientific and practical firm ALTAN”

Email: valent_04@mail.ru
Russian Federation, Barnaul

S. A. Lazarev

Altai State Medical University (ASMU)

Email: valent_04@mail.ru
ORCID iD: 0000-0001-7748-0784
Russian Federation, 40, Lenin Ave., Barnaul, 656038

V. A. Marchkov

OOO “Scientific and practical firm ALTAN”

Email: valent_04@mail.ru
Russian Federation, Barnaul

D. I. Ganov

Altai State Medical University (ASMU)

Email: valent_04@mail.ru
ORCID iD: 0000-0002-7118-1668
Russian Federation, 40, Lenin Ave., Barnaul, 656038

References

  1. Seer.cancer.gov [Intrenet]. Surveillance, Epidemiology, and End Rezults Program. Prostate cancer. National Cancer Institute [cited 2021 Oct 1]. Available from: http://www.seer.cancer.gov.
  2. Bray F, Ferlay J, Soerjomataram I, et al. Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2018;68(6):394-424. doi: 10.3322/caac.21492
  3. World Health Organisation [Internet]. World Source: Globocan 2018 [cited 2021 Oct 1]. Available from: http://gco.iarc.fr/today/data/factsheets/populations/900-world-fact-sheets.pdf.
  4. Kaprin AD, Starinsky VV, Shakhzadova AO. Malignant neoplasms in Russia in 2019 (morbidity and mortality). Moscow: MNIOI im. P.A. Herzen – branch FGBI «NERC» Ministry of health of Russia; 2020. (In Russ).
  5. Kaprin AD, Starinsky VV, Shakhzadova AO. The state of cancer care in Russia in 2020. Moscow: MNIOI im. P.A. Herzen – branch FGBI «NERC» Ministry of health of Russia; 2021. (In Russ).
  6. Sergeeva NS, Skachkova TE, Marshutina NV et al. Clinical significance of PSA-associated tests in the diagnosis and staging of prostate cancer. P.A. Herzen journal of oncology. 2018; 7(1):55-67. (In Russ). doi: 10.17116/onkolog20187155-67
  7. Pushkar’ DY, Rasner PI. Differential diagnosis of cancer and benign prostatic hyperplasia. Russkii meditsinskii zhurnal. 2014;22(17):1298-1303. (In Russ).
  8. Assotsiatsiya onkologov Rossii. Prostate cancer. Clinical recommendations. Moscow; 2020. 140 p. (In Russ).
  9. Lazarev AF. Territorial Cancer Registry. Certificate of state registration of a computer program (2008611703). March 31, 2008. (20088610743).Feb 26, 2008. Federal Service for Intellectual Property, patents and trademarks. (In Russ).
  10. Lazarev AF, Lazarev SA, editors. Formation of cancer risk groups using digital technologies: guidelines for doctors, residents and students. Barnaul: AGMU – branch FGBI «AGMU» Ministry of health of Russia; 2020. (In Russ).
  11. Patent RUS №2692987/ 28.06.2019. Lazarev AF. Method for determining the risk of prostate cancer. Available from: https://patenton.ru/patent/RU2692987C1. (In Russ).
  12. Russian Certificate of state registration of a computer program N 2019663514, 17.10.2019. Lazarev AF, Pokornyak VP, Marchkov VA, Lazarev SA, Petrova VD. Automated program for early diagnosis of prostate cancer (prostate cancer). Application no.2019662379.

Supplementary files

Supplementary Files
Action
1. Fig. 1. Options for self-testing in the "Automated program for early diagnosis of prostate cancer": QR code and Internet link

Download (137KB)
2. Fig. 2. High-risk precancer registry for prostate cancer

Download (255KB)
3. Fig. 3. Result of the analysis of the "Automated program for early diagnosis of prostate cancer", patient N.

Download (347KB)
4. Fig. 4. Result of the analysis of the "Automated program for early diagnosis of prostate cancer", patient K.

Download (347KB)

Copyright (c) 2020 Eco-Vector



This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies